Bioventus Inc. (BVS) is a Healthcare stock trading at $14.31 (as of 2026-08-20), with a market capitalization of $1.01B and a trailing P/E of 18.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Bioventus Inc. is a medical device company focused on developing and commercializing clinical treatment solutions intended to support the body’s natural healing. Its portfolio spans pain therapies (including non-surgical joint injections), surgical products (such as bone graft substitutes and ultrasonic devices), and restorative and rehabilitation offerings used across orthopedic and related care settings by physicians in clinics, ambulatory centers, and hospitals.
Bioventus develops and sells clinical medical device treatments that support the body's natural healing, including non-surgical joint pain injection therapies and peripheral nerve stimulation, plus surgical solutions like bone graft substitutes and ultrasonic medical devices, generating revenue from product sales in the United States and internationally.
Bioventus profits from selling its device and treatment portfolio, so performance depends on sales volume and product mix across Pain Treatments and Surgical Solutions, with negative pressure highlighted by the reported Global Sales Decline of Restorative Therapies Products.
| Pain Tx | $0.1B |
| Surgical Solns | $0.1B |
Business quality (Weak): Clear product categories are available, but an official, fully reconciled segment breakdown is not provided, and one KPI is an internal trend metric rather than a standard market operating gauge.
Valuation: At 21× earnings, BVS trades 36% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $14.31 |
| Market Cap | $1.01B |
| P/E Ratio | 18.6 |
| EV / EBITDA | 11.8 |
| Price / Book | 3.65 |
| Price / Sales | 1.74 |
| FCF Yield | 9.3% |
| DCF Value (model) | $3.43 |
| DCF Upside vs Price | -76.0% |
| Revenue (TTM) | $568.09M |
| Net Margin | 4.0% |
| Revenue Growth (YoY) | 3.8% |
| EPS Growth (YoY) | 345.5% |
| FCF Growth (YoY) | -25.1% |
| Altman Z-Score | 1.90 (grey) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 18.6 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | -13.8% |
| vs Industry | -43.4% |
| Top Institutional Holder | Essex Woodlands Management, Inc. ($118.88M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Robert E. Claypoole |
| Employees | 930 |
| Country | US |
| IPO Date | 2021-02-11 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.